These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 24549055)

  • 1. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
    Castéra L; Krieger S; Rousselin A; Legros A; Baumann JJ; Bruet O; Brault B; Fouillet R; Goardon N; Letac O; Baert-Desurmont S; Tinat J; Bera O; Dugast C; Berthet P; Polycarpe F; Layet V; Hardouin A; Frébourg T; Vaur D
    Eur J Hum Genet; 2014 Nov; 22(11):1305-13. PubMed ID: 24549055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of BRCA1/2 large genomic rearrangement including BRCA1 promoter-region deletions using next-generation sequencing.
    Han E; Yoo J; Chae H; Lee S; Kim DH; Kim KJ; Kim Y; Kim M
    Clin Chim Acta; 2020 Jun; 505():49-54. PubMed ID: 32092317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers.
    Rajkumar T; Meenakumari B; Mani S; Sridevi V; Sundersingh S
    Asian Pac J Cancer Prev; 2015; 16(13):5211-7. PubMed ID: 26225655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow.
    Schmidt AY; Hansen TVO; Ahlborn LB; Jønson L; Yde CW; Nielsen FC
    J Mol Diagn; 2017 Nov; 19(6):809-816. PubMed ID: 28822785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations.
    Zanella I; Merola F; Biasiotto G; Archetti S; Spinelli E; Di Lorenzo D
    Exp Mol Pathol; 2017 Apr; 102(2):314-320. PubMed ID: 28263838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.
    Sahin I; Saat H
    Mol Biol Rep; 2021 Jun; 48(6):5057-5062. PubMed ID: 34146199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
    Gervas P; Klyuch B; Denisov E; Kiselev A; Molokov A; Pisareva L; Malinovskaya E; Choynzonov E; Cherdyntseva N
    Mol Biol Rep; 2019 Oct; 46(5):5537-5541. PubMed ID: 31273614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
    Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
    BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.
    Trujillano D; Weiss ME; Schneider J; Köster J; Papachristos EB; Saviouk V; Zakharkina T; Nahavandi N; Kovacevic L; Rolfs A
    J Mol Diagn; 2015 Mar; 17(2):162-70. PubMed ID: 25556971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.